{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:24:13Z","timestamp":1788834253569,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-024-02595-7","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:02:24Z","timestamp":1723633344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-PD-1\/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7553-1016","authenticated-orcid":false,"given":"Mohammad Sina","family":"Mirjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8485-8721","authenticated-orcid":false,"given":"Muhammad Hussain","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6964-8101","authenticated-orcid":false,"given":"Pouria","family":"Delbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shahir","family":"Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-4152","authenticated-orcid":false,"given":"Yalda","family":"Ghazizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5306-7377","authenticated-orcid":false,"given":"Mohammad Amin","family":"Ghezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-9124","authenticated-orcid":false,"given":"Romina Hamidi","family":"Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4224-7813","authenticated-orcid":false,"given":"Kimia Ghazi","family":"Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9470-8135","authenticated-orcid":false,"given":"Sohrab","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poriya","family":"Minaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeyedMohammad","family":"Eazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali Abouei","family":"Mehrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-874X","authenticated-orcid":false,"given":"Sajjad","family":"Ahmadpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"11","key":"2595_CR1","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.3390\/cancers15112922","volume":"15","author":"OJ van Not","year":"2023","unstructured":"van Not OJ et al (2023) A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 15(11):2922","journal-title":"Cancers (Basel)"},{"key":"2595_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2018.05.012","volume":"99","author":"L Milsch","year":"2018","unstructured":"Milsch L, Gesierich A, Kreft S, Livingstone E, Zimmer L, Goebeler M et al (2018) Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. Eur J Cancer 99:58\u201365","journal-title":"Eur J Cancer"},{"issue":"1","key":"2595_CR3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-018-4374-x","volume":"18","author":"E Vosoughi","year":"2018","unstructured":"Vosoughi E, Lee JM, Miller JR, Nosrati M, Minor DR, Abendroth R et al (2018) Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer 18(1):490","journal-title":"BMC Cancer"},{"issue":"5","key":"2595_CR4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/NRL.0000000000000439","volume":"27","author":"D Gritsch","year":"2022","unstructured":"Gritsch D et al (2022) In Patients With Melanoma Brain Metastases, Is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic. Neurologist 27(5):290\u2013297","journal-title":"Neurologist"},{"issue":"3","key":"2595_CR5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1684\/ejd.2019.3558","volume":"29","author":"S Bocquet-Tremoureux","year":"2019","unstructured":"Bocquet-Tremoureux S, Scharbarg E, Nguyen JM, Varey E, Quereux G, Saint-Jean M et al (2019) Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. Eur J Dermatol 29(3):315\u2013321","journal-title":"Eur J Dermatol"},{"issue":"15","key":"2595_CR6","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2016.34.15_suppl.2071","volume":"34","author":"I Dagogo-Jack","year":"2016","unstructured":"Dagogo-Jack I et al (2016) Retrospective analysis of activity of pembrolizumab (pembro) in melanoma patients (pts) with brain metastasis (BM). J Clin Oncol 34(15):2071","journal-title":"J Clin Oncol"},{"key":"2595_CR7","first-page":"165","volume":"17","author":"ST Becker","year":"2019","unstructured":"Becker ST et al (2019) Immuno-combination Therapy with Nivolumab and Ipilimumab in Melanoma Brain Metastases - Efficacy and Toxicity. J Dtsch Dermatol Ges 17:165\u2013165","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"2595_CR8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19(5):672\u2013681","journal-title":"Lancet Oncol"},{"issue":"15","key":"2595_CR9","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","volume":"39","author":"GV Long","year":"2021","unstructured":"Long GV et al (2021) Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). J Clin Oncol 39(15):9508","journal-title":"J Clin Oncol"},{"issue":"12","key":"2595_CR10","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bjc.2017.142","volume":"116","author":"S Parakh","year":"2017","unstructured":"Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S et al (2017) Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer 116(12):1558\u20131563","journal-title":"Br J Cancer"},{"issue":"6","key":"2595_CR11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CMR.0000000000000700","volume":"30","author":"M Marcaillou","year":"2020","unstructured":"Marcaillou M et al (2020) PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma. Melanoma Res 30(6):580\u2013589","journal-title":"Melanoma Res"},{"key":"2595_CR12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2023.04.018","volume":"188","author":"S Manacorda","year":"2023","unstructured":"Manacorda S et al (2023) Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids. Eur J Cancer 188:98\u2013107","journal-title":"Eur J Cancer"},{"key":"2595_CR13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103\u2013112","journal-title":"J Clin Epidemiol"},{"key":"2595_CR14","doi-asserted-by":"publisher","unstructured":"Deeks JJ, et al (2019) Analysing data and undertaking meta-analyses, in Cochrane Handbook for Systematic Reviews of Interventions. p 241\u2013284. https:\/\/doi.org\/10.1002\/9781119536604.ch10","DOI":"10.1002\/9781119536604.ch10"},{"issue":"5","key":"2595_CR15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","volume":"24","author":"C Alvarez-Breckenridge","year":"2019","unstructured":"Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A et al (2019) Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control. Oncologist 24(5):671\u2013679","journal-title":"Oncologist"},{"issue":"5","key":"2595_CR16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.5114\/ada.2018.79940","volume":"36","author":"B Cybulska-Stopa","year":"2019","unstructured":"Cybulska-Stopa B, \u0141ugowska I, Jagodzi\u0144ska-Mucha P, Kose\u0142a-Paterczyk H, Kozak K, Klimczak A et al (2019) Immune checkpoint inhibitors therapy in older patients (\u2265\u200970 years) with metastatic melanoma: a multicentre study. Postepy Dermatol Alergol 36(5):566\u2013571","journal-title":"Postepy Dermatol Alergol"},{"issue":"3","key":"2595_CR17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/CJI.0000000000000159","volume":"40","author":"I Dagogo-Jack","year":"2017","unstructured":"Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ (2017) A retrospective analysis of the efficacy of pembrolizumab in melanoma patients with brain metastasis. J Immunother 40(3):108\u2013113","journal-title":"J Immunother"},{"issue":"17","key":"2595_CR18","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","volume":"27","author":"AM Di Giacomo","year":"2021","unstructured":"Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P et al (2021) Primary Analysis and 4-Year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases. Clin Cancer Res 27(17):4737\u20134745","journal-title":"Clin Cancer Res"},{"key":"2595_CR19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2021.02.037","volume":"149","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou F, Zaremba A, Allayous C, K\u00e4hler KC, Gerard CL, Festino L et al (2021) Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. Eur J Cancer 149:37\u201348","journal-title":"Eur J Cancer"},{"key":"2595_CR20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2021.07.028","volume":"156","author":"ML Hilbers","year":"2021","unstructured":"Hilbers ML, Dimitriou F, Lau P, Bhave P, McArthur GA, Zimmer L et al (2021) Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. Eur J Cancer 156:149\u2013163","journal-title":"Eur J Cancer"},{"issue":"1","key":"2595_CR21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T et al (2019) Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37(1):52\u201360","journal-title":"J Clin Oncol"},{"issue":"8","key":"2595_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000385","volume":"44","author":"GS Naik","year":"2021","unstructured":"Naik GS, Buchbinder EI, Cohen JV, Manos MP, Johnson AEW, Bowling P et al (2021) Long-term overall survival and predictors in anti-PD-1-naive melanoma patients with brain metastases treated with immune checkpoint inhibitors in the real-world setting: a multicohort study. J Immunother 44(8):307\u2013318","journal-title":"J Immunother"},{"issue":"23","key":"2595_CR23","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1002\/cncr.32454","volume":"125","author":"G Schvartsman","year":"2019","unstructured":"Schvartsman G, Ma J, Bassett RL Jr, Haydu LE, Amaria RN, Hwu P et al (2019) Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer 125(23):4193\u20134202","journal-title":"Cancer"},{"issue":"2","key":"2595_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cncr.30946","volume":"124","author":"S Sloot","year":"2018","unstructured":"Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mul\u00e9 JJ et al (2018) Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer 124(2):297\u2013305","journal-title":"Cancer"},{"key":"2595_CR25","doi-asserted-by":"crossref","unstructured":"Stoff R, Asher N, Laks S, Steinberg Y, Schachter J, Shapira-Frommer R et al (2023) Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma. Front Oncol 13:1180988","DOI":"10.3389\/fonc.2023.1180988"},{"issue":"8","key":"2595_CR26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722\u2013730","journal-title":"N Engl J Med"},{"key":"2595_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejca.2021.02.030","volume":"149","author":"S Tjulandin","year":"2021","unstructured":"Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S et al (2021) Novel PD-1 inhibitor prolgolimab: expanding non-resectable\/metastatic melanoma therapy choice. Eur J Cancer 149:222\u2013232","journal-title":"Eur J Cancer"},{"key":"2595_CR28","doi-asserted-by":"crossref","first-page":"5524685","DOI":"10.1155\/2021\/5524685","volume":"2021","author":"J Valentin","year":"2021","unstructured":"Valentin J, Fert\u00e9 T, Dorizy-Vuong V, Dousset L, Prey S, Dutriaux C et al (2021) Real-world survival in patients with metastatic melanoma after discontinuation of anti-PD-1 immunotherapy for objective response or adverse effects: a retrospective study. J Oncol 2021:5524685","journal-title":"J Oncol"},{"issue":"2","key":"2595_CR29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12094-021-02692-9","volume":"24","author":"CM Vila","year":"2022","unstructured":"Vila CM, Moreno FA, Est\u00e9banez MM, Ares GR, Villacampa G, Dashti P et al (2022) Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution. Clin Transl Oncol 24(2):319\u2013330","journal-title":"Clin Transl Oncol"},{"key":"2595_CR30","first-page":"5","volume":"19","author":"M Weichenthal","year":"2021","unstructured":"Weichenthal M, Mohr P, Leiter-Stoppke U, Ugurel S, Kahler K, Gutzmer R et al (2021) The effects of brain metastases in melanoma patients on anti-PD1 antibody therapy with pembrolizumab. Journal der Deutschen Dermatologischen Gesellschaft 19:5\u20136","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"2595_CR31","volume-title":"Brain metastases from primary tumors","author":"I Glitza","year":"2016","unstructured":"Glitza I et al (2016) Brain metastases from primary tumors. Academic Press, London, UK"},{"issue":"8","key":"2595_CR32","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696","journal-title":"Cancer"},{"issue":"5","key":"2595_CR33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaoncol.2015.1206","volume":"1","author":"S Goyal","year":"2015","unstructured":"Goyal S et al (2015) Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol 1(5):668\u2013676","journal-title":"JAMA Oncol"},{"issue":"21","key":"2595_CR34","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/cncr.32375","volume":"125","author":"E Rulli","year":"2019","unstructured":"Rulli E et al (2019) The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis. Cancer 125(21):3776\u20133789","journal-title":"Cancer"},{"issue":"1","key":"2595_CR35","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4","volume":"10","author":"L Sun","year":"2020","unstructured":"Sun L et al (2020) Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep 10(1):2083","journal-title":"Sci Rep"},{"key":"2595_CR36","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.critrevonc.2019.102830","volume":"144","author":"F Petrelli","year":"2019","unstructured":"Petrelli F et al (2019) Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. Crit Rev Oncol Hematol 144:102830","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2595_CR37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976\u2013983","journal-title":"Lancet Oncol"},{"issue":"3","key":"2595_CR38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2005.06.032","volume":"63","author":"S Demaria","year":"2005","unstructured":"Demaria S et al (2005) Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 63(3):655\u2013666","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2595_CR39","doi-asserted-by":"publisher","unstructured":"Cortez MA, et al (2016) PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 108(1). https:\/\/doi.org\/10.1093\/jnci\/djv303","DOI":"10.1093\/jnci\/djv303"},{"issue":"10","key":"2595_CR40","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jtho.2016.06.002","volume":"11","author":"J Khalifa","year":"2016","unstructured":"Khalifa J et al (2016) Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. J Thorac Oncol 11(10):1627\u20131643","journal-title":"J Thorac Oncol"},{"key":"2595_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.08.003","volume":"50","author":"D Franceschini","year":"2016","unstructured":"Franceschini D et al (2016) Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Cancer Treat Rev 50:1\u20138","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2595_CR42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J et al (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"21","key":"2595_CR43","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006\u20132017","journal-title":"N Engl J Med"},{"issue":"4","key":"2595_CR44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3348\/kjr.2020.0728","volume":"22","author":"PH Kim","year":"2021","unstructured":"Kim PH et al (2021) Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean J Radiol 22(4):584\u2013595","journal-title":"Korean J Radiol"},{"key":"2595_CR45","doi-asserted-by":"crossref","first-page":"113542","DOI":"10.1016\/j.ejca.2024.113542","volume":"199","author":"M Mandal\u00e0","year":"2024","unstructured":"Mandal\u00e0 M et al (2024) Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study. Eur J Cancer 199:113542","journal-title":"Eur J Cancer"},{"key":"2595_CR46","doi-asserted-by":"crossref","first-page":"v414","DOI":"10.1093\/annonc\/mdx376.033","volume":"28","author":"SM Nguyen","year":"2017","unstructured":"Nguyen SM et al (2017) Melanoma brain metastases patients treated with stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone: a systematic review with meta-analysis. Ann Oncol 28:v414\u2013v415","journal-title":"Ann Oncol"},{"key":"2595_CR47","doi-asserted-by":"crossref","first-page":"104227","DOI":"10.1016\/j.critrevonc.2023.104227","volume":"194","author":"C Li","year":"2024","unstructured":"Li C et al (2024) Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review. Crit Rev Oncol Hematol 194:104227","journal-title":"Crit Rev Oncol Hematol"},{"key":"2595_CR48","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jocn.2019.12.063","volume":"73","author":"FA McHugh","year":"2020","unstructured":"McHugh FA et al (2020) Metastatic melanoma: Surgical treatment of brain metastases \u2013 Analysis of 110 patients. J Clin Neurosci 73:144\u2013149","journal-title":"J Clin Neurosci"},{"issue":"1","key":"2595_CR49","doi-asserted-by":"crossref","first-page":"Cns93","DOI":"10.2217\/cns-2022-0014","volume":"12","author":"KR Tringale","year":"2023","unstructured":"Tringale KR et al (2023) Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure. CNS Oncol 12(1):Cns93","journal-title":"CNS Oncol"},{"key":"2595_CR50","doi-asserted-by":"crossref","first-page":"1025664","DOI":"10.3389\/fonc.2022.1025664","volume":"12","author":"XL Tan","year":"2022","unstructured":"Tan XL et al (2022) Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases. Front Oncol 12:1025664","journal-title":"Front Oncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-024-02595-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-024-02595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:22:51Z","timestamp":1741350171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-024-02595-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2595"],"URL":"https:\/\/doi.org\/10.1007\/s10143-024-02595-7","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is deemed to exempt to received ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"434"}}